Active pharmaceutical ingredient (API) Global Market – Forecast To 2029

Publishing Date : February, 2023
Report Code : HCPH 0100
Price:
Single license $4,950
Site license $6,750
Global license $9,000


Note: The report would be dispatched after confirmation of payment

Generally, each drug made up of two components that are API and excipients, having curative activity. APIs are often known as bulk pharmaceuticals and most of all APIs are in powder form. Active Pharmaceutical Ingredients (APIs) are active substances in a drug intended to achieve pharmacological activity which is having a direct effect on disease treatment. APIs are synthesized based on chemical synthesis, fermentation, biotechnological methods or enhanced from the natural source.

The API global market is expected to grow at a high single digit CAGR from 2022 to 2029 to reach $388,002.4 million by 2029. The major factors driving the API market are increasing incidence and prevalence of various chronic diseases, adoption of biologics in disease management & increasing regulatory approvals and increasing R&D expenditure & expansion of manufacturing facilities. Whereas, growing scope for HPAPI and next generation therapeutics such as cell therapy and gene therapy, increasing patent expiration and trend of outsourcing are providing immense opportunity to the API market.  The high risk of contamination during the manufacturing of API, high cost for manufacturing of complex and advanced API’s, presence of alternatives and stringent regulations associated with pharma manufacturing are hindering the market growth.

The global API market is mainly segmented based on synthesis, business type, application, and geography. Based on synthesis, the API global market is segmented into synthetic API, biotech API and HPAPI. Among these, synthetic API accounted for the highest revenue in 2022 and is expected to grow at a mid single digit CAGR from 2022 to 2029. Biotech API is expected to grow at a double digit CAGR from 2022 to 2029. Based on product type, Biotech API is further segmented into antibodies, recombinant proteins, vaccines, cell therapy, gene therapy and others. Among these, antibodies segment accounted for the highest revenue in 2022 and is expected to grow at a double digit CAGR from 2022 to 2029. Gene Therapy is expected to grow at a mid teen CAGR from 2022 to 2029. Antibodies global market is further classified into monoclonal antibody, bispecific and others. Among these, Monoclonal Antibody segment is accounted for the highest revenue in 2022 and is expected to grow at a double digit CAGR from 2022 to 2029. Bispecific segment is expected to grow at an early teen CAGR from 2022 to 2029. Based on the customer base, the global biotech API is further segmented into biologics and biosimilars. Biologics accounted for the highest revenue in 2022 and is expected to grow at a high single digit CAGR from 2022 to 2029. Biosimilar API segment is expected to grow at a mid teen CAGR from 2022 to 2029.

Synthetic API global market based on customer base is further segmented into branded and generic synthetic API. Among these, branded synthetic AP global market accounted for the highest revenue in 2022 and is expected to grow at a mid single digit CAGR from 2022 to 2029. Generic synthetic API market is expected to grow at a high single digit CAGR from 2022 to 2029.

The HPAPI global market is estimated to be $XX million in 2022 and is expected to grow at a double digit CAGR from 2022 to 2029. The global HPAPI market based on customer base is further classified into branded and generic HPAPI. Among these, branded HPAPI accounted for the highest revenue in 2022 and is expected to grow at a high single digit CAGR from 2022 to 2029. Generic HPAPI is expected to grow at an early teen CAGR of 11.8% from 2022 to 2029.

Based on business type, the API global market is segmented into Captive and Merchant API. Among these, captive API accounted for the highest revenue in 2022 and is expected to grow at a mid single digit CAGR from 2022 to 2029. Merchant API segment is expected to grow at high single digit CAGR from 2022 to 2029. The Captive API global market is further segmented into branded and generic API. Among these, branded API accounted for the highest revenue in 2022 and is expected to grow at a mid single digit CAGR from 2022 to 2029. The merchant API global market is further segmented into branded and generic API. Among these, branded merchant API accounted for the highest revenue in 2022 and is expected to grow at a high single digit CAGR from 2022 to 2029. Generic Merchant API segment is expected to grow at early teen CAGR from 2022 to 2029.

The API global market based on application is segmented into infectious diseases, oncology, cardiovascular diseases, central nervous system, pulmonary diseases, gastrointestinal diseases, endocrine diseases, metabolic disorders, genito-urinary diseases, musculoskeletal diseases and others such as ophthalmology, nephrology, hepatology, ENT, dental, dermatology, and pain management. Among the application, the infectious disease segment accounted for the highest revenue in 2022 and is expected to grow at a mid single digit CAGR from 2022 to 2029. Oncology is expected to grow at a double digit CAGR from 2022 to 2029.

In synthetic API global market based on application, infectious disease segment accounted for the highest revenue in 2022 and is expected to grow at a mid single digit CAGR from 2022 to 2029. Oncology is expected to grow at a high single digit CAGR from 2022 to 2029. In Biotech API global market based on application, musculoskeletal diseases segment accounted for the largest revenue in 2022 and is expected to grow at a double digit CAGR from 2022 to 2029. The oncology segment is expected to grow at a strong early teen CAGR from 2022 to 2029. The HPAPI global market based on application, the oncology segment accounted for the largest revenue in 2022 and is expected to grow at a early teen CAGR from 2022 to 2029.

The active pharmaceutical Ingredients global market based on region is segmented as North America, Europe, Asia-Pacific, and the Rest of the world (ROW). Among the region, North America accounted for the highest revenue in 2022 and is expected to grow at a mid single digit CAGR from 2022 to 2029. Growing pharma R&D expenditure, increasing development of new drugs over the time, increasing approval of generics and biosimilars, growing biopharmaceutical drugs pipelines, presence of number of API manufacturing facilities for all regulated drug products, increasing scope of highly potent drugs, government support to expand the domestic pharmaceutical manufacturing facilities and increase in the prevalence of infectious diseases, cancer, central nervous system associated diseases, cardiac disease, and musculoskeletal disorder are some of the major diseases that are driving the market growth. Asia-Pacific is the fastest-growing region with a high single digit CAGR from 2022 to 2029. The factors such as increasing generic pharmaceuticals and vaccines production, number of pharma companies with a strong network of manufacturing facilities, increasing outsourcing with number of CMO’s and expanding manufacturing facilities, increasing development of new pharma and biopharma drugs, growing biotech R&D investment, presence of number of innovative biotech startups, presence of dedicated departments to support biotechnology research, increasing government investment to support the pharma and biotech industry, low labor cost, and increased prevalence of infectious and other chronic diseases are driving the market growth.

Some of the key players of Active pharmaceutical Ingredient (API) market are Catalent Inc (U.S.), Divis Laboratories (India), Lonza Group (Switzerland), Samsung Biologics, (South Korea), Wuxi Biologics (China), Wuxi Apptec (China), Pfizer Inc. (U.S.), EuroAPI (France), Thermo Fisher Scientific (Patheon N.V.) (U.S.) and Teva Pharmaceutical Industries Limited (Israel).

 

The report provides an in-depth market analysis of the above-mentioned segments across the following regions:

  • North America
  • U.S.
  • Rest of North America
  • Europe
  • Italy
  • Germany
  • France
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • India
  • Rest of APAC
  • Rest of the World (RoW)
  • Brazil
  • Rest of Latin America
  • Middle East and Others

TABLE OF CONTENTS

  • 1     EXECUTIVE SUMMARY
  • 2     INTRODUCTION
    • 2.1     KEY TAKEAWAYS
    • 2.2     SCOPE OF THE REPORT
    • 2.3     REPORT DESCRIPTION
    • 2.4     MARKETS COVERED
    • 2.5     STAKEHOLDERS
    • 2.6     RESEARCH METHODOLOGY
      • 2.6.1     MARKET SIZE ESTIMATION
      • 2.6.2     MARKET BREAKDOWN AND DATA TRIANGULATION
      • 2.6.3     SECONDARY SOURCES
      • 2.6.4     PRIMARY SOURCES
      • 2.6.5     KEY DATA POINTS FROM SECONDARY SOURCES
      • 2.6.6     KEY DATA POINTS FROM PRIMARY SOURCES
      • 2.6.7     ASSUMPTIONS
  • 3     MARKET ANALYSIS
    • 3.1     INTRODUCTION
    • 3.2     MARKET SEGMENTATION
    • 3.3     FACTORS INFLUENCING MARKET
      • 3.3.1     DRIVERS AND OPPORTUNITIES
        • 3.3.1.1     Increasing incidence and prevalence of chronic, communicable and autoimmune diseases
        • 3.3.1.2     Adoption of biologics in disease management and increasing regulatory approvals
        • 3.3.1.3     Increasing investment in research and development (R&D) and expansion of manufacturing facilities
        • 3.3.1.4     Patent expiration of major drugs
        • 3.3.1.5     Increasing scope of HPAPI and advanced next generation biologics market
        • 3.3.1.6     Increasing trend of outsourcing and adoption in emerging market
        • 3.3.1.7     Increase in the geriatric population
      • 3.3.2     RESTRAINTS AND THREATS
        • 3.3.2.1     Contamination of API
        • 3.3.2.2     High cost for manufacturing APIs
        • 3.3.2.3     A requirement of highly skilled technicians
        • 3.3.2.4     Pierce competition between API players
        • 3.3.2.5     Presence of alternatives
        • 3.3.2.6     Stringent regulatory policies and environmental concerns
    • 3.4     REGULATORY AFFAIRS
      • 3.4.1     INTERNATIONAL ORGANIZATION FOR STANDARDIZATION
        • 3.4.1.1     ISO 9001: 2015 QUALITY MANAGEMENT SYSTEM
        • 3.4.1.2     ISO 13408 ASEPTIC PROCESSING
        • 3.4.1.3     ISO 14644-1 CLEAN ROOM STANDARDS
      • 3.4.2     U.S.
      • 3.4.3     CANADA
      • 3.4.4     MEXICO
      • 3.4.5     EUROPE
      • 3.4.6     CHINA
      • 3.4.7     INDIA
      • 3.4.8     JAPAN
      • 3.4.9     AUSTRALIA
      • 3.4.10     SOUTH KOREA
      • 3.4.11     LATIN AMERICA
      • 3.4.12     MIDDLE EAST
    • 3.5     TECHNOLOGICAL ADVANCEMENTS
      • 3.5.1     INTRODUCTION
      • 3.5.2     AUTOMATION AND CONTROL
      • 3.5.3     CONTINUOUS FLOW MANUFACTURING
      • 3.5.4     CRYOGENIC TECHNOLOGY
      • 3.5.5     SINGLE - USE SYSTEM (SUS)
      • 3.5.6     ARTIFICIAL INTELLIGENCE IN API MANUFACTURING
      • 3.5.7     CHEMISTRY IN WATER
      • 3.5.8     m-RNA TECHNOLOGY IN VACCINE MANUFACTURING
      • 3.5.9     ADVANCEMENTS IN HPAPI MANUFACTURING
    • 3.6     PORTER’S FIVE FORCE ANALYSIS
      • 3.6.1     THREAT OF NEW ENTRANTS
      • 3.6.2     THREAT OF SUBSTITUTES
      • 3.6.3     BARGAINING POWER OF SUPPLIERS
      • 3.6.4     BARGAINING POWER OF BUYERS
      • 3.6.5     COMPETITIVE RIVALRY
    • 3.7     SUPPLY CHAIN ANALYSIS
    • 3.8     MARKET SHARE ANALYSIS
      • 3.8.1     MARKET SHARE ANALYSIS OF MERCHANT API GLOBAL MARKET
      • 3.8.2     MARKET SHARE ANALYSIS OF MERCHANT SYNTHETIC API GLOBAL MARKET
      • 3.8.3     MARKET SHARE ANALYSIS OF MERCHANT BIOTECH API GLOBAL MARKET
    • 3.9     FDA APPROVED API MANUFACTURING UNITS
    • 3.1     PHARMACEUTICAL API PRODUCTION VOLUME
    • 3.11     PATENT EXPIRY AND ANDA APPROVALS
    • 3.12     DRUG MASTER FILING (DMF)
    • 3.13     REPURPOSED DRUGS FOR COVID-19 TREATMENT
    • 3.14     ACQUISITION, MERGER, AND EXPANSIONS IN API MANUFACTURING
    • 3.15     SELECTED TOP SELLING API
    • 3.16     API MANUFACTURERS REVENUE AND CAPABILITIES TABLE
  • 4     API GLOBAL MARKET, BASED ON SYNTHESIS
    • 4.1     INTRODUCTION
    • 4.2     SYNTHETIC API
      • 4.2.1     SYNTHETIC API BASED ON CUSTOMER BASE
        • 4.2.1.1     Branded synthetic API
        • 4.2.1.2     Generic synthetic API
    • 4.3     BIOTECH API
      • 4.3.1     ANTIBODIES
        • 4.3.1.1     Monoclonal antibody
        • 4.3.1.2     Bispecific antibody
        • 4.3.1.3     Others (polyclonal antibody, antibody fragments)
      • 4.3.2     RECOMBINANT PROTEINS
      • 4.3.3     VACCINES
      • 4.3.4     GENE THERAPY
      • 4.3.5     CELL THERAPY
      • 4.3.6     OTHER BIOTECH API
      • 4.3.7     BIOTECH API BASED ON CUSTOMER BASE
        • 4.3.7.1     BIOLOGIC API
        • 4.3.7.2     BIOSIMILAR API
    • 4.4     HPAPI
      • 4.4.1     HPAPI BASED ON CUSTOMER BASE
        • 4.4.1.1     BRANDED HPAPI
        • 4.4.1.2     GENERIC HPAPI
  • 5     API GLOBAL MARKET, BASED ON BUSINESS TYPE
    • 5.1     INTRODUCTION
    • 5.2     CAPTIVE API BASED ON TYPE
      • 5.2.1     BRANDED CAPTIVE API
      • 5.2.2     GENERIC CAPTIVE API
    • 5.3     MERCHANT API BASED ON TYPE
      • 5.3.1     BRANDED MERCHANT API
      • 5.3.2     GENERIC MERCHANT API
  • 6     API GLOBAL MARKET, BASED ON APPLICATION
    • 6.1     INTRODUCTION
    • 6.2     INFECTIOUS DISEASES
    • 6.3     ONCOLOGY
    • 6.4     CARDIOVASCULAR DISEASES
    • 6.5     CENTRAL NERVOUS SYSTEM
    • 6.6     PULMONARY DISEASES
    • 6.7     GASTROINTESTINAL DISEASES
    • 6.8     ENDOCRINE DISEASES
    • 6.9     METABOLIC DISORDERS
    • 6.1     GENITOURINARY DISEASES
    • 6.11     MUSCULOSKELETAL DISEASES
    • 6.12     OTHER APPLICATIONS (NEPHROLOGY, HEPATOLOGY, OPTHALMOLOGY, DENTAL, PAIN MANAGEMENT, DERMATOLOGY,ENT ETC.,)
  • 7     REGIONAL ANALYSIS
    • 7.1     INTRODUCTION
    • 7.2     NORTH AMERICA
      • 7.2.1     U.S.
      • 7.2.2     REST OF NORTH AMERICA
    • 7.3     EUROPE
      • 7.3.1     ITALY
      • 7.3.2     GERMANY
      • 7.3.3     FRANCE
      • 7.3.4     REST OF EUROPE
    • 7.4     APAC
      • 7.4.1     CHINA
      • 7.4.2     JAPAN
      • 7.4.3     INDIA
      • 7.4.4     REST OF APAC
    • 7.5     ROW
      • 7.5.1     BRAZIL
      • 7.5.2     REST OF LATAM
      • 7.5.3     MIDDLE EAST & OTHERS
  • 8     COMPETITIVE LANDSCAPE
    • 8.1     INTRODUCTION
    • 8.2     COLLABORATION, PARTNERSHIP AND AGREEMENT
    • 8.3     EXPANSION
    • 8.4     APPROVALS
    • 8.5     NEW PRODUCT, SERVICE AND TECHNOLOGY LAUNCH
    • 8.6     ACQUISITION
    • 8.7     OTHERS
  • 9     MAJOR COMPANIES
    • 9.1     CATALENT INC.
      • 9.1.1     OVERVIEW
      • 9.1.2     FINANCIALS
      • 9.1.3     SERVICE PORTFOLIO
      • 9.1.4     KEY DEVELOPMENTS
      • 9.1.5     BUSINESS STRATEGY
      • 9.1.6     SWOT ANALYSIS
    • 9.2     DIVIS LABORATORIES
      • 9.2.1     OVERVIEW
      • 9.2.2     FINANCIALS
      • 9.2.3     PRODUCT PORTFOLIO
      • 9.2.4     KEY DEVELOPMENTS
      • 9.2.5     BUSINESS STRATEGY
      • 9.2.6     SWOT ANALYSIS
    • 9.3     EUROAPI
      • 9.3.1     OVERVIEW
      • 9.3.2     FINANCIALS
      • 9.3.3     PRODUCT PORTFOLIO
      • 9.3.4     KEY DEVELOPMENTS
      • 9.3.5     BUSINESS STRATEGY
      • 9.3.6     SWOT ANALYSIS
    • 9.4     LONZA GROUP LTD.
      • 9.4.1     OVERVIEW
      • 9.4.2     FINANCIALS
      • 9.4.3     SERVICES PORTFOLIO
      • 9.4.4     KEY DEVELOPMENTS
      • 9.4.5     BUSINESS STRATEGY
      • 9.4.6     SWOT ANALYSIS
    • 9.5     PFIZER INC.
      • 9.5.1     OVERVIEW
      • 9.5.2     FINANCIALS
      • 9.5.3     SEVICE PORTFOLIO
      • 9.5.4     KEY DEVELOPMENTS
      • 9.5.5     BUSINESS STRATEGY
      • 9.5.6     SWOT ANALYSIS
    • 9.6     SAMSUNG BIOLOGICS CO. LTD.
      • 9.6.1     OVERVIEW
      • 9.6.2     FINANCIALS
      • 9.6.3     SERVICE PORTFOLIO
      • 9.6.4     KEY DEVELOPMENTS
      • 9.6.5     BUSINESS STRATEGY
      • 9.6.6     SWOT ANALYSIS
    • 9.7     TEVA PHARMACEUTICAL INDUSTRIES LIMITED.
      • 9.7.1     OVERVIEW
      • 9.7.2     FINANCIALS
      • 9.7.3     PRODUCT PORTFOLIO
      • 9.7.4     KEY DEVELOPMENTS
      • 9.7.5     BUSINESS STRATEGY
      • 9.7.6     SWOT ANALYSIS
    • 9.8     THERMO FISHER SCIENTIFIC INC
      • 9.8.1     OVERVIEW
      • 9.8.2     FINANCIALS
      • 9.8.3     SERVICE PORTFOLIO
      • 9.8.4     KEY DEVELOPMENTS
      • 9.8.5     BUSINESS STRATEGY
      • 9.8.6     SWOT ANALYSIS
    • 9.9     WUXI APPTEC CO., LTD.
      • 9.9.1     OVERVIEW
      • 9.9.2     FINANCIALS
      • 9.9.3     SERVICE PORTFOLIO
      • 9.9.4     KEY DEVELOPMENTS
      • 9.9.5     BUSINESS STRATEGY
      • 9.9.6     SWOT ANALYSIS
    • 9.1     WUXI BIOLOGICS (CAYMAN) INC.
      • 9.10.1     OVERVIEW
      • 9.10.2     FINANCIALS
      • 9.10.3     SERVICE PORTFOLIO
      • 9.10.4     KEY DEVELOPMENTS
      • 9.10.5     BUSINESS STRATEGY
      • 9.10.6     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     API GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 2     GLOBAL SMALL MOLECULE API REVENUE ($MN), AVERAGE SELLING PRICE ($/KG) AND PRODUCTION IN TONS BASED ON APPLICATION (2022)
      • TABLE 3     GLOBAL SMALL MOLECULE VOLUME AND UTILIZATION, CMO VOLUME AND UTILIZATION, (2021-2029) (MILLION LITRES)
      • TABLE 4     GLOBAL SMALL MOLECULE API PRODUCTION, BASED ON APPLICATION, (2021-2029) (TONS)
      • TABLE 5     GLOBAL BIOLOGICS VOLUME AND UTILIZATION, CMO VOLUME AND UTILIZATION, (2021-2029) (MILLION LITRES)
      • TABLE 6     GLOBAL SMALL MOLECULE API PRODUCTION, (2021-2029) (METRIC TONS)
      • TABLE 7     GLOBAL BIOLOGICS API PRODUCTION, (2021-2029) (METRIC TONS)
      • TABLE 8     GLOBAL API PRODUCTION, (2021-2029) (METRIC TONS)
      • TABLE 9     PATENT EXPIRY OF SYNTHETIC API DRUGS, (2022 – 2024)
      • TABLE 10     PATENT EXPIRY OF BIOTECH API DRUGS, (2018 – 2030)
      • TABLE 11     ANDA APPROVALS: SMALL MOLECULES - GENERICS, (2020 – 2022)
      • TABLE 12     FDA APPROVED BIOSIMILARS, (2021 - 2022)
      • TABLE 13     EXPANSION (2021– 2022)
      • TABLE 14     COMPANIES ACQUISITION AND MERGER, (2021 – 2022)
      • TABLE 15     API GLOBAL MARKET REVENUE, BASED ON SYNTHESIS, (2021-2029) ($MN)
      • TABLE 16     SYNTHETIC API GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 17     SYNTHETIC API GLOBAL MARKET REVENUE, BASED ON CUSTOMER BASE, (2021-2029) ($MN)
      • TABLE 18     BRANDED SYNTHETIC API GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 19     GENERIC SYNTHETIC API GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 20     BIOTECH API GLOBAL MARKET REVENUE, BASED ON PRODUCT TYPE, (2022-2029) ($MN)
      • TABLE 21     BIOTECH API GLOBAL MARKET REVENUE, BY REGION, (2021-2029) ($MN)
      • TABLE 22     FDA APPROVED BIOLOGICS (2019-2021)
      • TABLE 23     ANTIBODY GLOBAL MARKET REVENUE, BASED ON PRODUCT TYPE (2021-2029) ($MN)
      • TABLE 24     ANTIBODY GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
      • TABLE 25     MONOCLONAL ANTIBODIES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 26     BI-SPECIFIC ANTIBODIES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 27     OTHERS GLOBAL MARKET REVENUE, BASED ON REGION, (2022-2029) ($MN)
      • TABLE 28     RECOMBINANT PROTEINS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 29     VACCINES GLOBAL MARKET REVENUE, BASED ON REGION, (2022-2029) ($MN)
      • TABLE 30     GENE THERAPY GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 31     CELL THERAPY GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 32     OTHER BIOTECH API GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 33     BIOTECH API GLOBAL MARKET REVENUE, BASED ON CUSTOMER BASE, (2021-2029) ($MN)
      • TABLE 34     BIOLOGIC API GLOBAL MARKET REVENUE, BASED ON REGION, (2022-2029) ($MN)
      • TABLE 35     BIOSIMILAR API GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 36     HPAPI GLOBAL MARKET REVENUE, BY REGION, (2021-2029) ($MN)
      • TABLE 37     HPAPI GLOBAL MARKET REVENUE, BASED ON CUSTOMER BASE, (2021-2029) ($MN)
      • TABLE 38     BRANDED HPAPI GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 39     GENERIC HPAPI GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 40     API GLOBAL MARKET REVENUE, BASED ON BUSINESS TYPE, (2021-2029) ($MN)
      • TABLE 41     CAPTIVE API GLOBAL MARKET REVENUE, BASED ON TYPE, (2021-2029) ($MN)
      • TABLE 42     CAPTIVE API GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 43     BRANDED CAPTIVE API GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 44     GENERIC CAPTIVE API GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 45     MERCHANT API GLOBAL MARKET REVENUE, BASED ON TYPE, (2021-2029) ($MN)
      • TABLE 46     MERCHANT API GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 47     BRANDED MERCHANT API GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 48     GENERIC MERCHANT API GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 49     API GLOBAL MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
      • TABLE 50     SYNTHETIC API GLOBAL MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
      • TABLE 51     BIOTECH API GLOBAL MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
      • TABLE 52     HPAPI GLOBAL MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
      • TABLE 53     INFECTIOUS DISEASES API GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 54     SYNTHETIC INFECTIOUS DISEASES API GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 55     BIOTECH INFECTIOUS DISEASES API GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 56     HPAPI INFECTIOUS DISEASES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 57     ONCOLOGY API GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 58     SYNTHETIC ONCOLOGY API GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 59     BIOTECH ONCOLOGY API GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 60     HPAPI ONCOLOGY GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 61     CARDIOVASCULAR DISEASES API GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 62     SYNTHETIC CARDIOVASCULAR DISEASES API GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 63     BIOTECH CARDIOVASCULAR DISEASES API GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 64     HPAPI CARDIOVASCULAR DISEASES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 65     CENTRAL NERVOUS SYSTEM API GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 66     SYNTHETIC CENTRAL NERVOUS SYSTEM API GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 67     BIOTECH CENTRAL NERVOUS SYSTEM API GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 68     HPAPI CENTRAL NERVOUS SYSTEM GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 69     PULMONARY DISEASES API GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 70     SYNTHETIC PULMONARY DISEASES API GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 71     BIOTECH PULMONARY DISEASES API GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 72     HPAPI PULMONARY DISEASES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 73     GASTROINTESTINAL DISEASES API GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 74     SYNTHETIC GASTROINTESTINAL DISEASES API GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 75     BIOTECH GASTROINTESTINAL DISEASES API GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 76     HPAPI GASTROINTESTINAL DISEASES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 77     ENDOCRINE DISEASES API GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 78     SYNTHETIC ENDOCRINE DISEASES API GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 79     BIOTECH ENDOCRINE DISEASES API GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 80     HPAPI ENDOCRINE DISEASES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 81     METABOLIC DISORDERS API GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 82     SYNTHETIC METABOLIC DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2021-2029) ($MN)
      • TABLE 83     BIOTECH METABOLIC DISORDERS API GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 84     HPAPI METABOLIC DISORDERS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 85     GENITOURINARY DISEASES API GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 86     SYNTHETIC GENITOURINARY DISEASES API GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 87     BIOTECH GENITOURINARY DISEASES API GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 88     HPAPI GENITOURINARY DISEASES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 89     MUSCULOSKELETAL DISEASES API GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 90     SYNTHETIC MUSCULOSKELETAL DISEASES API GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 91     BIOTECH MUSCULOSKELETAL DISEASES API GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 92     HPAPI MUSCULOSKELETAL DISEASES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 93     OTHER APPLICATIONS API GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 94     SYNTHETIC OTHER APPLICATIONS API GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 95     BIOTECH OTHER APPLICATIONS API GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 96     HPAPI OTHER APPLICATIONS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 97     API GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 98     NORTH AMERICA API MARKET REVENUE, BASED ON SYNTHESIS, (2021-2029) ($MN)
      • TABLE 99     NORTH AMERICA BIOTECH API MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 100     NORTH AMERICA ANTIBODIES MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 101     NORTH AMERICA SYNTHETIC API MARKET REVENUE, BASED ON CUSTOMER BASE, (2021-2029) ($MN)
      • TABLE 102     NORTH AMERICA BIOTECH API MARKET REVENUE, BASED ON CUSTOMER BASE, (2021-2029) ($MN)
      • TABLE 103     NORTH AMERICA HPAPI MARKET REVENUE, BASED ON CUSTOMER BASE, (2021-2029) ($MN)
      • TABLE 104     NORTH AMERICA API MARKET REVENUE, BASED ON BUSINESS TYPE, (2021-2029) ($MN)
      • TABLE 105     NORTH AMERICA CAPTIVE API MARKET REVENUE, BASED ON TYPE, (2021-2029) ($MN)
      • TABLE 106     NORTH AMERICA MERCHANT API MARKET REVENUE, BASED ON TYPE, (2021-2029) ($MN)
      • TABLE 107     NORTH AMERICA API MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
      • TABLE 108     NORTH AMERICA SYNTHETIC API MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
      • TABLE 109     NORTH AMERICA BIOTECH API MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
      • TABLE 110     NORTH AMERICA HPAPI MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
      • TABLE 111     NORTH AMERICA API MARKET REVENUE, BASED ON COUNTRY, (2021-2029) ($MN)
      • TABLE 112     EUROPE API MARKET REVENUE, BASED ON SYNTHESIS, (2021-2029) ($MN)
      • TABLE 113     EUROPE BIOTECH API MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 114     EUROPE ANTIBODIES MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 115     EUROPE SYNTHETIC API MARKET REVENUE, BASED ON CUSTOMER BASE, (2021-2029) ($MN)
      • TABLE 116     EUROPE BIOTECH API MARKET REVENUE, BASED ON CUSTOMER BASE, (2021-2029) ($MN)
      • TABLE 117     EUROPE HPAPI MARKET REVENUE, BASED ON CUSTOMER BASE, (2021-2029) ($MN)
      • TABLE 118     EUROPE API MARKET REVENUE, BASED ON BUSINESS TYPE, (2021-2029) ($MN)
      • TABLE 119     EUROPE CAPTIVE API MARKET REVENUE, BASED ON TYPE, (2021-2029) ($MN)
      • TABLE 120     EUROPE MERCHANT API MARKET REVENUE, BASED ON TYPE, (2021-2029) ($MN)
      • TABLE 121     EUROPE API MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
      • TABLE 122     EUROPE SYNTHETIC API MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
      • TABLE 123     EUROPE BIOTECH API MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
      • TABLE 124     EUROPE HPAPI MARKET REVENUE, BY APPLICATION, (2021-2029) ($MN)
      • TABLE 125     EUROPE API MARKET REVENUE, BY COUNTRY, (2021-2029) ($MN)
      • TABLE 126     APAC API MARKET REVENUE, BASED ON SYNTHESIS, (2021-2029) ($MN)
      • TABLE 127     APAC BIOTECH API MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 128     APAC ANTIBODIES MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 129     APAC SYNTHETIC API MARKET REVENUE, BASED ON CUSTOMER BASE, (2021-2029) ($MN)
      • TABLE 130     APAC BIOTECH API MARKET REVENUE, BASED ON CUSTOMER BASE, (2021-2029) ($MN)
      • TABLE 131     APAC HPAPI MARKET REVENUE, BASED ON CUSTOMER BASE, (2021-2029) ($MN)
      • TABLE 132     APAC API MARKET REVENUE, BASED ON BUSINESS TYPE, (2021-2029) ($MN)
      • TABLE 133     APAC CAPTIVE API MARKET REVENUE, BASED ON TYPE, (2021-2029) ($MN)
      • TABLE 134     APAC MERCHANT API MARKET REVENUE, BASED ON TYPE, (2021-2029) ($MN)
      • TABLE 135     APAC API MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
      • TABLE 136     APAC SYNTHETIC API MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
      • TABLE 137     APAC BIOTECH API MARKET REVENUE, BY APPLICATION, (2021-2029) ($MN)
      • TABLE 138     APAC HPAPI MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
      • TABLE 139     APAC API MARKET REVENUE, BASED ON COUNTRY, (2021-2029) ($MN)
      • TABLE 140     ROW API MARKET REVENUE, BASED ON SYNTHESIS, (2021-2029) ($MN)
      • TABLE 141     ROW BIOTECH API MARKET REVENUE, BASED ON PRODUCT TYPE, (2022-2029) ($MN)
      • TABLE 142     ROW ANTIBODIES MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 143     ROW SYNTHETIC API MARKET REVENUE, BASED ON CUSTOMER BASE, (2021-2029) ($MN)
      • TABLE 144     ROW BIOTECH API MARKET REVENUE, BASED ON CUSTOMER BASE, (2021-2029) ($MN)
      • TABLE 145     ROW HPAPI MARKET REVENUE, BASED ON CUSTOMER BASE, (2021-2029) ($MN)
      • TABLE 146     ROW API MARKET REVENUE, BASED ON BUSINESS TYPE, (2021-2029) ($MN)
      • TABLE 147     ROW CAPTIVE API MARKET REVENUE, BASED ON TYPE, (2021-2029) ($MN)
      • TABLE 148     ROW MERCHANT API MARKET REVENUE, BASED ON TYPE, (2021-2029) ($MN)
      • TABLE 149     ROW API MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
      • TABLE 150     ROW SYNTHETIC API MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
      • TABLE 151     ROW BIOTECH API MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
      • TABLE 152     ROW HPAPI MARKET REVENUE, BY APPLICATION, (2021-2029) ($MN)
      • TABLE 153     ROW API MARKET REVENUE, BASED ON COUNTRY, (2022-2029) ($MN)
      • TABLE 154     COLLABORATION, PARTNERSHIP AND AGREEMENT
      • TABLE 155     EXPANSION
      • TABLE 156     APPROVALS
      • TABLE 157     NEW PRODUCT, SERVICE AND TECHNOLOGY LAUNCH
      • TABLE 158     ACQUISITION
      • TABLE 159     OTHERS
      • TABLE 160     CATALENT INC: TOTAL REVENUE AND R&D EXPENSES (2021-2023) (Q1) ($MN)
      • TABLE 161     CATALENT INC: TOTAL REVENUE, BY SEGMENT, (2021-2023) (Q1) ($MN)
      • TABLE 162     CATALENT INC: TOTAL REVENUE, BY GEOGRPAHY, (2021-2023) (Q1) ($MN)
      • TABLE 163     DIVIS LABORATORIES LTD: TOTAL REVENUE AND R&D EXPENSES (2020-2022) (Q2) ($MN)
      • TABLE 164     DIVIS LABORATORIES LTD: TOTAL REVENUE, BY GEOGRAPHY (2020-2022) (Q2) ($MN)
      • TABLE 165     EUROAPI: TOTAL REVENUE AND R&D EXPENSES, (2020 - 2022) (Q2) ($MN)
      • TABLE 166     EUROAPI: TOTAL REVENUE, BY SEGMENTS, (2020-2022) (Q2) ($MN)
      • TABLE 167     LONZA GROUP: TOTAL REVENUE & R&D EXPENSES (2020 -2022) (Q2) ($MN)
      • TABLE 168     LONZA GROUP: TOTAL REVENUE, BY SEGMENT, (2020 -2022) (Q2) ($MN)
      • TABLE 169     LONZA GROUP: TOTAL REVENUE, BY GEOGRAPHY (2020 -2022) (Q2) ($MN)
      • TABLE 170     PFIZER INC: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (Q3) ($MN)
      • TABLE 171     PFIZER INC: TOTAL REVENUE, BY SEGMENTS, (2020-2022) (Q3) ($MN)
      • TABLE 172     PFIZER INC: TOTAL REVENUE, BY GEOGRAPHY, (2020-2022) (Q3) ($MN)
      • TABLE 173     SAMSUNG BIOLOGICS CO: TOTAL REVENUE (2020-2022) (Q3) ($MN)
      • TABLE 174     TEVA PHARMACEUTICAL INDUSTRIES LIMITED: TOTAL REVENUE AND R&D EXPENSES (2020-2022) (Q3) ($MN)
      • TABLE 175     TEVA PHARMACEUTICAL INDUSTRIES LIMITED: TOTAL REVENUE BY SEGMENT (2020-2022) (Q3) ($MN)
      • TABLE 176     TEVA PHARMACEUTICAL INDUSTRIES LIMITED: TOTAL REVENUE BY GEOGRAPHY (2020-2022) (Q3) ($MN)
      • TABLE 177     THERMO FISHER SCIENTIFIC INC.: TOTAL REVENUE AND R&D EXPENSES (2020-2022) (Q3) ($MN)
      • TABLE 178     THERMO FISHER SCIENTIFIC INC.: TOTAL REVENUE, BY SEGMENT, (2020-2022) (Q3) ($MN)
      • TABLE 179     THERMO FISHER SCIENTIFIC INC.: TOTAL REVENUE, BY GEOGRAPHY (2020-2022)(Q3) ($MN)
      • TABLE 180     WUXI APPTEC CO., LTD.: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (Q3) ($MN)
      • TABLE 181     WUXI APPTEC CO., LTD.: TOTAL REVENUE, BY SEGMENTS, (2020-2022) (Q3) ($MN)
      • TABLE 182     WUXI BIOLOGICS: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (Q2)($MN)
      • TABLE 183     WUXI BIOLOGICS: TOTAL REVENUE, BY SEGMENTS, (2020-2022) (Q2) ($MN)
      • TABLE 184     WUXI BIOLOGICS: TOTAL REVENUE, BY GEOGRAPHY, (2020-2022) (Q2) ($MN)

      LIST OF FIGURES

      • FIGURE 1     API GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
      • FIGURE 2     RESEARCH METHODOLOGY: API GLOBAL MARKET
      • FIGURE 3     API GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
      • FIGURE 4     API GLOBAL MARKET: FORECASTING MODEL
      • FIGURE 5     API GLOBAL MARKET: MARKET BREAKDOWN AND DATA TRIANGULATION
      • FIGURE 6     API GLOBAL MARKET SEGMENTATION
      • FIGURE 7     MARKET DYNAMICS
      • FIGURE 8     API GLOBAL MARKET: PORTER’S ANALYSIS
      • FIGURE 9     API GLOBAL MARKET: SUPPLY CHAIN ANALYSIS
      • FIGURE 10     MERCHANT API GLOBAL MARKET SHARE ANALYSIS, BY MAJOR PLAYERS, 2022 (%)
      • FIGURE 11     MERCHANT SYNTHETIC API GLOBAL MARKET SHARE ANALYSIS, BY MAJOR PLAYERS, 2022 (%)
      • FIGURE 12     MERCHANT BIOTACH API GLOBAL MARKET SHARE ANALYSIS, BY MAJOR PLAYERS, 2022 (%)
      • FIGURE 13     FDA APPROVED GLOBAL API MANUFACTURING LANDSCAPE
      • FIGURE 14     SMALL MOLECULE API PRODUCTION BASED ON APPLICATION (2022), IN-HOUSE V/S CMO (2021 – 2029) (TONS) AND GLOBAL MANUFACTURING CAPACITIES (2022) (LITRES)
      • FIGURE 15     GLOBAL TOTAL API AND CMO PRODUCTION (2021 – 2029) (METRIC TONS)
      • FIGURE 16     PATENT EXPIRY OF SMALL MOLECULES (2022-2024)
      • FIGURE 17     PATENT EXPIRY OF SYNTHETIC API DRUGS, BASED ON APPLICATION SHARE (2022-2024) (%)
      • FIGURE 18     ANDA APPROVALS OF SYNTHETIC API DRUGS, BASED ON APPLICATION SHARE (2020-2022) (%)
      • FIGURE 19     API DMF FILED BASED ON REGION AND COUNTRIES (NO’S) (2021)
      • FIGURE 20     API DMF FILED, BASED ON COMPANY (2021) (NO’S)
      • FIGURE 21     API GLOBAL MARKET SHARE, BASED ON SYNTHESIS, BASED ON CUSTOMER BASE AND BIOTECH API BASED ON PRODUCT TYPE (2022) (%)
      • FIGURE 22     SYNTHETIC API GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 23     BIOTECH API GLOBAL MARKET SHARE, BY REGION, (2022 V/S 2029) (%)
      • FIGURE 24     ANTIBODY GLOBAL MARKET SHARE, BASED ON PRODUCT TYPE (2022 VS 2029) (%)
      • FIGURE 25     VACCINES GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 26     BIOLOGIC API GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 27     API GLOBAL MARKET SHARE BASED ON BUSINESS TYPE, CAPTIVE API AND MERCHANT API BASED ON TYPE (2022) (%)
      • FIGURE 28     CAPTIVE API GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 29     GENERIC MERCHANT API GLOBAL MARKET SHARE, BY REGION, (2022 V/S 2029) (%)
      • FIGURE 30     API GLOBAL MARKET SHARE, BASED ON APPLICATION (2022 VS 2029) (%)
      • FIGURE 31     BIOTECH INFECTIOUS DISEASES API GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 32     METABOLIC DISORDER API GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 33     BIOTECH METABOLIC DISORDERS API GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 34     HPAPI METABOLIC DISORDERS API GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 35     SYNTHETIC MUSCULOSKELETAL DISEASES GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 36     API GLOBAL MARKET REVENUE, BASED REGION (2021-2029) ($MN), CAGR (%)
      • FIGURE 37     API GLOBAL MARKET SHARE, BASED ON REGION AND BASED ON COUNTRY (2022) (%)
      • FIGURE 38     NORTH AMERICA API MARKET REVENUE, BY SYNTHESIS AND BIOTECH API MARKET, BASED ON PRODUCT TYPE (2022) ($ MN)
      • FIGURE 39     NORTH AMERICA ANTIBODIES MARKET SHARE BASED PRODUCT TYPE (2022 V/S 2029) (%)
      • FIGURE 40     NORTH AMERICA SYNTHETIC API, BIOTECH API AND HPAPI MARKET SHARE, BASED ON CUSTOMER BASE (2022 V/S 2029) (%)
      • FIGURE 41     NORTH AMERICA API MARKET SHARE, BY BUSINESS TYPE, CAPTIVE API AND MERCHANT API MARKET, BASED ON TYPE (2022 V/S 2029) (%)
      • FIGURE 42     NORTH AMERICA API MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029) (%)
      • FIGURE 43     NORTH AMERICA SYNTHETIC API MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029) (%)
      • FIGURE 44     NORTH AMERICA BIOTECH API MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029) (%)
      • FIGURE 45     NORTH AMERICA HPAPI MARKET SHARE, BASED ONAPPLICATION (2022 V/S 2029) (%)
      • FIGURE 46     NORTH AMERICA API MARKET SHARE, BASED ON COUNTRY (2022 V/S 2029) (%)
      • FIGURE 47     U.S. API MARKET REVENUE, BASED ON SYNTHESIS TYPE, BIOTECH API MARKET REVENUE, BASED ON PRODUCT TYPE AND API MARKET, BASED ON BUSINESS TYPE (2022 V/S 2029) ($MN)
      • FIGURE 48     U.S. API MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 49     U.S. SYNTHETIC API MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 50     U.S. BIOTECH API MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 51     U.S. HPAPI MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 52     REST OF N.A. API MARKET REVENUE, BASED ON BUSINESS TYPE, BIOTECH API MARKET REVENUE, BASED ON PRODUCT TYPE AND API MARKET, BASED ON BUSINESS TYPE (2022 V/S 2029) ($MN)
      • FIGURE 53     REST OF N.A. API MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 54     REST OF N.A. SYNTHETIC API MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 55     REST OF N.A. BIOTECH API MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 56     REST OF N.A. HPAPI MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 57     EUROPE API MARKET REVENUE, BASED ON SYNTHESIS AND BIOTECH API MARKET, BASED ON PRODUCT TYPE (2022) ($ MN)
      • FIGURE 58     EUROPR ANTIBODIES MARKET SHARE BASED PRODUCT TYPE (2022 V/S 2029) (%)
      • FIGURE 59     EUROPE SYNTHETIC API, BIOTECH API AND HPAPI MARKET SHARE, BASED ON CUSTOMER BASE (2022 V/S 2029) (%)
      • FIGURE 60     EUROPE API MARKET SHARE BASED ON BUSINESS TYPE, CAPTIVE API AND MERCHANT API MARKET, BASED ON TYPE (2022 V/S 2029) (%)
      • FIGURE 61     EUROPE API MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029) (%)
      • FIGURE 62     EUROPE SYNTHETIC API MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029) (%)
      • FIGURE 63     EUROPE BIOTECH API MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029) (%)
      • FIGURE 64     EUROPE HPAPI MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029) (%)
      • FIGURE 65     EUROPE API MARKET SHARE, BASED ON COUNTRY (2022 V/S 2029) (%)
      • FIGURE 66     ITALY API MARKET REVENUE, BASED ON BUSINESS TYPE, BIOTECH API MARKET REVENUE, BASED ON PRODUCT TYPE AND API MARKET, BASED ON BUSINESS TYPE (2022 V/S 2029) ($MN)
      • FIGURE 67     ITALY API MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 68     ITALY SYNTHETIC API MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 69     ITALY BIOTECH API MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 70     ITALY HPAPI MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 71     GERMANY API MARKET REVENUE, BASED ON BUSINESS TYPE, BIOTECH API MARKET REVENUE, BASED ON PRODUCT TYPE AND API MARKET, BASED ON BUSINESS TYPE (2022 V/S 2029) ($MN)
      • FIGURE 72     GERMANY API MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 73     GERMANY SYNTHETIC API MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 74     GERMANY BIOTECH API MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 75     GERMANY HPAPI MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 76     FRANCE API MARKET REVENUE, BASED ON BUSINESS TYPE, BIOTECH API MARKET REVENUE, BASED ON PRODUCT TYPE AND API MARKET, BASED ON BUSINESS TYPE (2022 V/S 2029) ($MN)
      • FIGURE 77     FRANCE API MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 78     FRANCE SYNTHETIC API MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 79     FRANCE BIOTECH API MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 80     FRANCE HPAPI MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 81     REST OF EUROPE API MARKET REVENUE, BASED ON BUSINESS TYPE, BIOTECH API MARKET REVENUE, BASED ON PRODUCT TYPE AND API MARKET, BASED ON BUSINESS TYPE (2022 V/S 2029) ($MN)
      • FIGURE 82     REST OF EUROPE API MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 83     REST OF EUROPE SYNTHETIC API MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 84     REST OF EUROPE BIOTECH API MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 85     REST OF EUROPE HPAPI MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 86     APAC API MARKET REVENUE, BASED ON SYNTHESIS AND BIOTECH API MARKET, BASED ON PRODUCT TYPE (2022 V/S 2029) ($ MN)
      • FIGURE 87     APAC ANTIBODIES MARKET SHARE, BASED ON SYNTHESIS PRODUCT TYPE (2022 V/S 2029) (%)
      • FIGURE 88     APAC SYNTHETIC API, BIOTECH API AND HPAPI MARKET SHARE, BASED ON CUSTOMER BASE (2022 V/S 2029) (%)
      • FIGURE 89     APAC API MARKET SHARE BASED ON BUSINESS TYPE, CAPTIVE API AND MERCHANT API MARKET, BASED ON TYPE (2022 V/S 2029) (%)
      • FIGURE 90     APAC API MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029) (%)
      • FIGURE 91     APAC SYNTHETIC API MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029) (%)
      • FIGURE 92     APAC BIOTECH API MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029) (%)
      • FIGURE 93     APAC HPAPI MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029) (%)
      • FIGURE 94     APAC API MARKET SHARE, BASED ON COUNTRY (2020 V/S 2027) (%)
      • FIGURE 95     CHINA API MARKET REVENUE, BASED ON BUSINESS TYPE, BIOTECH API MARKET REVENUE, BASED ON PRODUCT TYPE AND API MARKET, BASED ON BUSINESS TYPE (2022 V/S 2029) ($MN)
      • FIGURE 96     CHINA API MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 97     CHINA SYNTHETIC API MARKET REVENUE, BASED ON APPLICATION, (2022 V/S 2029) ($MN)
      • FIGURE 98     CHINA BIOTECH API MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 99     CHINA HPAPI MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 100     JAPAN API MARKET REVENUE, BASED ON BUSINESS TYPE, BIOTECH API MARKET REVENUE, BASED ON PRODUCT TYPE AND API MARKET, BASED ON BUSINESS TYPE (2022 V/S 2029) ($MN)
      • FIGURE 101     JAPAN API MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 102     JAPAN SYNTHETIC API MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 103     JAPAN BIOTECH API MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 104     JAPAN HPAPI MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 105     INDIA API MARKET REVENUE, BASED ON BUSINESS TYPE, BIOTECH API MARKET REVENUE, BASED ON PRODUCT TYPE AND API MARKET, BASED ON BUSINESS TYPE (2022 V/S 2029) ($MN)
      • FIGURE 106     INDIA API MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 107     INDIA SYNTHETIC API MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 108     INDIA BIOTECH API MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 109     INDIA HPAPI MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 110     REST OF APAC API MARKET REVENUE, BASED ON BUSINESS TYPE, BIOTECH API MARKET REVENUE, BASED ON PRODUCT TYPE AND API MARKET, BASED BUSINESS TYPE (2022 V/S 2029) ($MN)
      • FIGURE 111     REST OF APAC API MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 112     REST OF APAC SYNTHETIC API MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 113     REST OF APAC BIOTECH API MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 114     REST OF APAC HPAPI MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 115     ROW API MARKET REVENUE, BASED ON SYNTHESIS AND BIOTECH API MARKET, BASED ON TYPE (2022) ($ MN)
      • FIGURE 116     ROW ANTIBODIES MARKET SHARE, BASED ON PRODUCT TYPE (2022 VS 2029) (%)
      • FIGURE 117     ROW SYNTHETIC API, BIOTECH API AND HPAPI MARKET SHARE, BASED ON CUSTOMER BASE (2022 V/S 2029) (%)
      • FIGURE 118     ROW API MARKET SHARE, BASED ON BUSINESS TYPE, CAPTIVE API AND MERCHANT API MARKET, BASED ON TYPE (2022 V/S 2029) (%)
      • FIGURE 119     ROW API MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029) (%)
      • FIGURE 120     ROW SYNTHETIC API MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029) (%)
      • FIGURE 121     ROW BIOTECH API MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029) (%)
      • FIGURE 122     ROW HPAPI MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029) (%)
      • FIGURE 123     ROW API SHARE, BASED ON COUNTRY (2022 V/S 2029) (%)
      • FIGURE 124     BRAZIL API MARKET REVENUE, BASED ON BUSINESS TYPE, BIOTECH API MARKET REVENUE, BASED ON PRODUCT TYPE AND API MARKET, BASED ON BUSINESS TYPE (2022 V/S 2029) ($MN)
      • FIGURE 125     BRAZIL API MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 126     BRAZIL SYNTHETIC API MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 127     BRAZIL BIOTECH API MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 128     BRAZIL HPAPI MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 129     REST OF LATAM API MARKET REVENUE, BASED ON BUSINESS TYPE, BIOTECH API MARKET REVENUE, BASED ON PRODUCT TYPE AND API MARKET, BASED ON BUSINESS TYPE (2022 V/S 2029) ($MN)
      • FIGURE 130     REST OF LATAM API MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 131     REST OF LATAM SYNTHETIC API MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 132     REST OF LATAM BIOTECH API MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 133     REST OF LATAM HPAPI MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 134     MIDDLE EAST & OTHERS API MARKET REVENUE, BASED ON BUSINESS TYPE, BIOTECH API MARKET REVENUE, BASED ON PRODUCT TYPE AND API MARKET, BASED ON BUSINESS TYPE (2022 V/S 2029) ($MN)
      • FIGURE 135     MIDDLE EAST & OTHERS API MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 136     MIDDLE EAST & OTHERS SYNTHETIC API MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 137     MIDDLE EAST & OTHERS BIOTECH API MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 138     MIDDLE EAST & OTHERS HPAPI MARKET REVENUE, BASED ON APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 139     KEY GROWTH STRATEGIES, (2020-2022)
      • FIGURE 140     SWOT: CATALENT INC.
      • FIGURE 141     SWOT: DIVIS LABORATORIES
      • FIGURE 142     SWOT: EUROAPI
      • FIGURE 143     SWOT: LONZA GROUP
      • FIGURE 144     SWOT: PFIZER INC.
      • FIGURE 145     SWOT: SAMSUNG BIOLOGICS
      • FIGURE 146     SWOT: TEVA PHARMACEUTICAL INDUSTRIES LIMITED
      • FIGURE 147     SWOT: THERMO FISHER SCIENTIFIC
      • FIGURE 148     SWOT: WUXI APPTECH
      • FIGURE 149     SWOT: WUXI BIOLOGICS

      LIST OF COMPANIES MENTIONED IN THE REPORT

      • 1     Aarti Drugs Ltd
      • 2     AbbVie Inc.
      • 3     ACIC Pharmaceuticals Inc.
      • 4     Adimmune Corporation
      • 5     Ajinomoto Bio-Pharma Services
      • 6     Albemarle Corporation
      • 7     Alembic Ltd
      • 8     Alkem laboratories Ltd.
      • 9     Almac Group
      • 10     Alven Laboratories S.r.o.
      • 11     Ambio Pharma Inc.
      • 12     Amneal Pharmaceuticals Inc.
      • 13     Apicore LLC
      • 14     Aragen Life Sciences (GVK Biosciences Private Limited)
      • 15     Arene Lifesciences Limited.
      • 16     AstraZeneca plc
      • 17     Aurobindo Pharma
      • 18     Ampac fine chemicals LLC
      • 19     Axplora
      • 20     BASF SE
      • 21     Bayer AG
      • 22     Bachem holding AG
      • 23     Bal Pharma Ltd.
      • 24     Biocon Limited
      • 25     Biogen Inc.
      • 26     Biomarin Pharmaceutical Inc
      • 27     Biophore India Pharmaceuticals Pvt. Ltd.
      • 28     Biosortia Pharmaceuticals Inc.
      • 29     Biotechnica Pharma Global
      • 30     Blanver
      • 31     Boehringer Ingelheim GmbH
      • 32     Brawn Biotech Ltd.
      • 33     Bristol-Myers Squibb Company
      • 34     Cadila Pharmaceuticals Limited
      • 35     Curia
      • 36     Catalent, Inc.
      • 37     Cayman Chemicals
      • 38     Celltrion Inc.,
      • 39     Cambrex Corporation
      • 40     Century Pharmaceuticals Ltd
      • 41     CFM Group (AMSA S.P.A)
      • 42     Changzhou Pharmaceutical Factory
      • 43     ChemCon GmbH
      • 44     China Chemical & Pharmaceutical Co., Ltd.
      • 45     Chongqing Huapont Pharmaceutical CO LTD,
      • 46     Cipla Limited
      • 47     CKD Bio
      • 48     Corden Pharma International (Germany)
      • 49     CSL Ltd
      • 50     Daiichi Sankyo Chemical Pharma Co Ltd
      • 51     Daito Pharmaceutical Co., Ltd
      • 52     Dishman Carbogen Amcis
      • 53     Dr.Reddy’s Laboratories
      • 54     Eisai Co., Ltd.
      • 55     Eli Lilly and Company
      • 56     Emcure Pharmaceuticals Ltd.
      • 57     Ercros S.A.
      • 58     Estechpharma Co., Ltd.
      • 59     Esteve Química SA
      • 60     Everest Organics Limited
      • 61     Evonik Industries AG
      • 62     F. Hoffmann-La Roche AG
      • 63     Fareva Group
      • 64     FIS Fabbrica Italiana Sintetici SPA
      • 65     Flamma S.p.A
      • 66     Formosa Laboratories, Inc.
      • 67     Fuji Chemical Industry Co.,Ltd
      • 68     Gentec Pharmaceutical Group S.A (DUKE CHEM and PHARMANOID)
      • 69     Gilead Sciences, Inc.
      • 70     Givaudan (Indena)
      • 71     Gland Pharma Limited
      • 72     GlaxoSmithKline plc
      • 73     Glenmark Pharmaceutical Ltd.
      • 74     GRANULES INDIA LTD.
      • 75     Grupo Ferrer Internacional S.A (Interquim, S.A)
      • 76     Harman Finochem Limited.
      • 77     Heraeus Holding GmbH
      • 78     Hetero Labs Ltd.
      • 79     Hikma pharmaceuticals
      • 80     Hybio Pharmaceutical Co., Ltd.
      • 81     Hikal Ltd.
      • 82     Ibio Inc
      • 83     Inabata Co. Ltd.
      • 84     INTAS PHARMACEUTICALS LTD,
      • 85     Jeil Pharmaceutical Co. Ltd.,
      • 86     Johnson and Johnson
      • 87     Johnson Matthey Pharma Services Inc.
      • 88     Jubilant lifesciences (Jubilant generics Ltd)
      • 89     Katsura Chemical Co.,Ltd.
      • 90     Kern Pharma, S.L.,
      • 91     Kleos pharma
      • 92     Koçak Farma Pharmaceutical
      • 93     Kosher Pharmaceuticals
      • 94     Krka, tovarna zdravil, d. d., Novo mesto
      • 95     Kyowa Hakko Kirin
      • 96     Laboratorium ofichem bv
      • 97     Lannett Company Inc.
      • 98     Laurus Labs
      • 99     Lebsa
      • 100     Lonza group
      • 101     Lusochimica S.p.A
      • 102     LOTUS Pharmaceutical Co., Ltd.
      • 103     Lesaffre (Gnosis S.p.A.)
      • 104     Magle Chemoswed AB
      • 105     Mallinckrodt Pharmaceuticals
      • 106     Medichem S.A
      • 107     Megafine Pharma Ltd
      • 108     Mehta API
      • 109     Merck KGaA
      • 110     Metrochem API
      • 111     Micro Labs LTD
      • 112     Minakem High Potent S.A.
      • 113     Moehs Iberica SL
      • 114     Molcan
      • 115     Morepen
      • 116     MSN Organics Pvt, Ltd.
      • 117     Natco Pharma
      • 118     Neuland laboratories Ltd.
      • 119     Novartis International AG
      • 120     Novo Holdings A/S
      • 121     Olainfarm JSC
      • 122     OLON S.P.A.
      • 123     Orchid Chemicals & Pharmaceuticals Ltd
      • 124     Orion (Fermion)
      • 125     Optimus Drugs Private LTD.
      • 126     Paratek Pharmaceuticals, Inc.
      • 127     Perrigo Company plc,
      • 128     Pfizer Inc.
      • 129     Phyton Biotech LLC
      • 130     Pierre Fabre
      • 131     Polpharma
      • 132     Prajna Generics Pvt. Ltd.
      • 133     Protex International (ICROM S.p.A.)
      • 134     Rablon Healthcare Pvt Ltd
      • 135     Saneca Pharmaceuticals a.s.
      • 136     Sanofi S.A.
      • 137     Solara Active Pharma
      • 138     Seikagaku Corporation
      • 139     SEQUENS (Wavelength Pharmaceuticals)
      • 140     Shiono Chemical Co., Ltd.
      • 141     SM BIOMED SDN. BHD
      • 142     Siegfried Holding AG
      • 143     Standard Chemical & Pharmaceutical Co.
      • 144     Sumitomo Dainippon Pharma Co., Ltd.
      • 145     Sun Pharmaceutical Industries Ltd
      • 146     Syn-tech chem. And Pharma.Co., Ltd
      • 147     Takeda Pharmaceutical Company Limited
      • 148     Temad Co.
      • 149     Teva Pharmaceutical industries Ltd.
      • 150     Umicore
      • 151     Unichem Laboratories LTD.
      • 152     Union Quimico Farmaceutica, S.A. UQUIFA,
      • 153     Venus Remedies Limited
      • 154     Vertex Pharmaceuticals Inc.